| Literature DB >> 28477628 |
Jinjian Fu1, Yanling Ding1, Ba Wei2, Lin Wang3, Shaolin Xu1, Peixu Qin1, Liuhua Wei4, Lijun Jiang5.
Abstract
BACKGROUND: Although the majority of Candida infections occur in the developing world, candidemia epidemiology is poorly understood in these countries. The aim of this study was to investigate the epidemiology of non-Candida albicans (non-C. albicans) candidemia among neonates at Liuzhou Maternity and Child Healthcare Hospital in China.Entities:
Keywords: Assisted reproductive technology; Candidemia; Infants; Non-C.albicans
Mesh:
Year: 2017 PMID: 28477628 PMCID: PMC5420153 DOI: 10.1186/s12879-017-2423-8
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Clinical characteristics of neonates between C.albicans and non-C.albicans
| Variable |
| non- |
| odds ratio (OR) (95%CI) |
|---|---|---|---|---|
| Demographics | ||||
| gestational age (wks) | 31.7 (27.6, 35.8) | 31.5 (27.7, 36.3) | 0.765 | |
| birth weight (g) | 1670.0 (962.1,2377.9) | 1417.6 (777.1,2058.1) | 0.128 | |
| male gender, n (%) | 22 (73.3) | 22 (56.4) | 0.150 | 0.47 (0.17–1.32) |
| admission age | 2.1 (2.0, 6.2) | 1.1 (0.6, 1.6) | 0.138 | |
| Risk factors | ||||
| necrotizing enterocolitis | 5 (16.7) | 12 (30.8) | 0.183 | 2.22 (0.69–7.21) |
| neurodevelopmental impairment | 7 (23.3) | 8 (20.5) | 0.778 | 0.85 (0.27–2.68) |
| maternal underlying diseases | 12 (40.0) | 18 (46.2) | 0.609 | 1.29 (0.50–3.36) |
| assisted reproductive technology | 5 (16.7) | 19 (48.7) | 0.008 | 4.75 (1.51–14.96) |
| vaginal birth | 19 (63.3) | 23 (59.0) | 0.713 | 1.20 (0.45–3.20) |
| fetal membrane rupture (h) | 16.4 (28.4, 61.2) | 26.6 (36.0, 89.2) | 0.459 | |
| congentital diseases | 13 (43.3) | 24 (61.5) | 0.135 | 2.09 (0.80–5.51) |
| abdominal surgery | 4 (13.3) | 6 (15.4) | 0.811 | 1.18 (0.30–4.63) |
| mechanical ventilation | 14 (46.7) | 29 (74.4) | 0.021 | 3.31 (1.20–9.15) |
| central venous catheter | 14 (46.7) | 27 (69.2) | 0.061 | 2.57 (0.96–6.91) |
| intubation | 10 (33.3) | 21 (53.8) | 0.092 | 2.33 (0.87–6.26) |
| pulmonary active substance use | 7 (23.3) | 9 (23.1) | 0.980 | 0.99 (0.32–3.04) |
| steroids use | 6 (20.0) | 9 (23.1) | 0.759 | 1.20 (0.38–3.84) |
| antacid use | 3 (10.3) | 8 (21.1) | 0.250 | 2.31 (0.56–9.63) |
| total parenteral nutrition | 23 (76.7) | 36 (92.3) | 0.080 | 3.65 (0.86–15.57) |
| hospitalization duration (d) | 43.8 (19.1, 78.5) | 49.1 (26.6, 71.6) | 0.367 | |
| 3rdcephalosporins use | 16 (55.2) | 23 (59.0) | 0.754 | 1.17 (0.44–3.08) |
| carbapenems use | 21 (70.0) | 30 (76.9) | 0.517 | 1.43 (0.49–4.20) |
| vancomycin use | 4 (13.3) | 6 (15.4) | 0.811 | 1.18 (0.30–4.63) |
| multiple antibiotic use | 19 (63.3) | 18 (46.2) | 0.158 | 0.50 (0.19–1.31) |
| antibiotic therapeutic duration (d) | 28.1 (10.0, 46.2) | 38.0 (19.3, 56.7) | 0.033 | |
| prophylaxis antifungal therapy | 19 (63.3) | 32 (82.1) | 0.084 | 2.65 (0.88–7.99) |
| antifungal therapeutic duration (d) | 7.9 (2.3, 13.5) | 8.8 (2.3, 15.3) | 0.535 | |
| Outcome | ||||
| death | 1 (3.3) | 5 (12.8) | 0.197 | 4.27 (0.47–38.62) |
Multivariate analysis for C.albicans and non-C.albicans
| Risk factor | Odds ratio | 95% CI |
|
|---|---|---|---|
| assisted reproductive technology | 4.52 | 1.39–14.77 | 0.012 |
| mechanical ventilation | 3.13 | 1.07–9.14 | 0.037 |